OOIR: Observatory of International Research

Papers

(The H4-Index of Leukemia is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Quantifying measurable residual disease correctly	2450
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)	2183
MCL1 as a therapeutic vulnerability in Burkitt lymphoma	182
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	164
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL	146
Cohesin mutations in acute myeloid leukemia	134
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis	127
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia	126
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core	116
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15	105
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study	99
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age	96
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication	94
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim–Chester disease in adults	91
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study	89
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	85
Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders	83
An MDM2 degrader for treatment of acute leukemias	82
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma	79
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial	77
Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia	76
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms	73
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase	73
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling	69
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)	69

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms	68
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial	67
Clonal medicine targeting DNA damage response eradicates leukemia	67
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells	67
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche	66
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009	66
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation	65
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries	64
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial	61
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation	61
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma	61
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia	59
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	58
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation	56
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	56
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	56
Real life evaluation of AlphaMissense predictions in hematological malignancies	55
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia	55
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells	53
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)	52
Nucleic acid therapeutics as differentiation agents for myeloid leukemias	52
Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation	52
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)	50
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia	50
A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy	50